Friday, 16 October 2026European Markets

POLARIS MEDIA Stock Was 9.85% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with POLARIS MEDIA (POL.OL) rising 9.85% to kr72.50 on Wednesday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0% to kr1,307.12, after two successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

POLARIS MEDIA's last close was kr66.00, 12% under its 52-week high of kr75.00.

About POLARIS MEDIA

Polaris Media ASA operates as a media house and printing company in Norway and Sweden. The company provides digital advertising services. It also prints group and external newspapers, including editorial supplements, advertising supplements and newspapers, civil prints, and other magazines/supplements. In addition, the company distributes newspapers, as well as parcels, mails, and food deliveries. The company was founded in 2008 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, POLARIS MEDIA has a trailing twelve months EPS of kr0.27.

PE Ratio

POLARIS MEDIA has a trailing twelve months price to earnings ratio of 268.52. Meaning, the purchaser of the share is investing kr268.52 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.47%.

Yearly Top and Bottom Value

POLARIS MEDIA's stock is valued at kr72.50 at 21:30 EST, under its 52-week high of kr75.00 and way higher than its 52-week low of kr47.20.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 3.65B for the twelve trailing months.

More news about POLARIS MEDIA (POL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com